The Subject Expert Committee (SEC) on Oncology and Hematology, functioning under the Central Drugs Standard Control ...

Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Herceptin SC binds selectively to a protein called human epidermal growth factor receptor 2 (HER2). HER2 is found in large amounts on the surface of some cancer cells.

I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...

Pertuzumab is a HER2 dimerization inhibitor that binds to a different epitope on HER2 than Herceptin. The drug inhibits HER2 dimer formation with other HER family members, such as HER3 and HER1.

Herceptin’s main US patent expires ... These are for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or g astroesophageal ...

Cancer patients’ journeys are complex and the benefit of a drug goes well beyond survival, even in cases of incurable and/or ...

One of the key characteristics is that unlike antibody-based HER2 drugs like Herceptin and Roche’s Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) it crosses the blood brain barrier, so ...

Between 5% and 17% of patients with gastric cancers are HER2-positive, according to study background. First-line treatment includes trastuzumab (Herceptin, Genentech) plus chemotherapy.

In the multicenter, open-label DESTINY-Breast09 study, patients with HER2-positive metastatic or advanced breast cancer were randomly assigned 1:1:1 to receive Enhertu at 5.4 milligram per kilogram ...

A suit cannot be maintained under the Civil law, merely based on an apprehension of litigation, without any concrete or ...